121 related articles for article (PubMed ID: 37775459)
1. Oligometastatic Prostate Cancer Treated with Stereotactic Body Radiation Therapy: The Role of Three-Dimensional Tumour Volume in Patient Survival.
Franzese C; Lucchini R; Roghi M; Badalamenti M; Baldaccini D; Comito T; Franceschini D; Navarria P; Di Cristina L; Lo Faro L; Galdieri C; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e649-e656. PubMed ID: 37775459
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of [
Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
[TBL] [Abstract][Full Text] [Related]
10. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
[TBL] [Abstract][Full Text] [Related]
13. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
[TBL] [Abstract][Full Text] [Related]
14. Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.
Deek MP; Yu C; Phillips R; Song DY; Deville C; Greco S; DeWeese TL; Antonarakis ES; Markowski M; Paller C; Denmeade S; Carducci M; Walsh PC; Pienta KJ; Eisenberger M; Tran PT
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):948-956. PubMed ID: 31419509
[TBL] [Abstract][Full Text] [Related]
15. CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.
Napieralska A; Miszczyk L; Stapor-Fudzinska M
Neoplasma; 2016; 63(2):304-12. PubMed ID: 26774153
[TBL] [Abstract][Full Text] [Related]
16. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
17. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival in patients with
Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]